Theravance settles YUPELRI patent litigation with Accord; generic entry allowed no earlier than April 23, 2039

Theravance Biopharma, Inc.

Settlement Agreement with Accord resolves Hatch-Waxman litigation over YUPELRI inhalation solution.
Accord granted royalty-free license to market generic YUPELRI on or after April 23, 2039, subject to customary exceptions.
Settlement subject to review by U.S. Department of Justice and Federal Trade Commission.
Patent litigation continues against five other ANDA filers: Cipla, Eugia, Lupin, Mankind, and Orbicular.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.